Supawit Tangpanithandee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Supawit Tangpanithandee has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Charat Thongprayoon
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN
24 shared publications - Wisit Cheungpasitporn
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
24 shared publications - Pajaree Krisanapan
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand
19 shared publications - Michael A. Mao
Division of Nephrology and Hypertension Mayo Clinic Jacksonville Florida USA
14 shared publications - Pattharawin Pattharanitima
Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand
11 shared publications - Wisit Kaewput
Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand
11 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published byĀ SAGE PublicationsĀ inĀ Therapeutic Advances in Drug Safety
- Vol.Ā 17
Drug interactions in rheumatoid arthritis: a disparity between electronic database prediction and real-world co-prescription with different large language models
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that often requires multi-drug regimens, which can increase the risk of drugādrug interactions (DDIs). Objective: To determine whether polypharmacy contributes to potential DDIs in patients with RA. Design: A retrospective observational study that integrates data from drug interaction databases and medical records, supplemented by artificial intelligence analysis. Methods: Twenty-one RA drugs and 54 commonly prescribed medicines were screened for potential DDIs using the Micromedex and WebMD databases and compared with real-world co-prescription at our hospital. The ChatGPT-5 and Gemini 2.5 large language models (LLMs) were also evaluated as āAI judgesā versus an expert rheumatologist to assess real-world co-prescription. This study was conducted from January to September 2025. Results: Among 75 frequently prescribed medicines in RA patients, 753 database-predicted potential DDIs were reported, with Micromedex showing 464 DDI pairs and WebMD showing 600 pairs. Both databases classified 47 serious potential DDIs as contraindicated or major, with high concordance. The main predicted DDI mechanisms were immunosuppression (27%), methotrexate toxicity (18%), and nephrotoxicity (12%), with tacrolimus (12%), methotrexate (10%), and infliximab (6%) as major culprit drugs. In real-world co-prescriptions, 259 RA patients showed methotrexate/naproxen (46.4%) and methotrexate/sulfasalazine (29.5%) as the most common real-world co-prescribing patterns with potential DDIs. BrennanāPrediger kappa values indicated fair agreement (0.3161) in the electronic database predictions and conditional agreement (0.9807) among preselected serious DDIs. The LLM evaluation revealed that advanced models (e.g., Gemini 2.5 Pro) provided finesse recommendations highly concordant with expert opinion, whereas simpler models were more conservatively aligned with database alerts. Conclusion: In both real-world co-prescription and database evaluation, serious potential DDIs were associated mainly with methotrexate toxicity. Based on these exploratory findings, advanced LLMs show potential to assist with the contextualizing rigid database alerts and supporting pragmatic clinical decision-making. However, expert clinical judgment and direct patient consultation remain essential to improve RA patient safety and medication adherence.
- 24 June 2026
- Published byĀ SAGE PublicationsĀ inĀ Therapeutic Advances in Drug Safety
- Vol.Ā 17
Open AccessDrug interactions in rheumatoid arthritis: a disparity between electronic database prediction and real-world co-prescription with different large language models
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that often requires multi-drug regimens, which can increase the risk of drugādrug interactions (DDIs). Objective: To determine whether polypharmacy contributes to potential DDIs in patients with RA. Design: A retrospective observational study that integrates data from drug interaction databases and medical records, supplemented by artificial intelligence analysis. Methods: Twenty-one RA drugs and 54 commonly prescribed medicines were screened for potential DDIs using the Micromedex and WebMD databases and compared with real-world co-prescription at our hospital. The ChatGPT-5 and Gemini 2.5 large language models (LLMs) were also evaluated as āAI judgesā versus an expert rheumatologist to assess real-world co-prescription. This study was conducted from January to September 2025. Results: Among 75 frequently prescribed medicines in RA patients, 753 database-predicted potential DDIs were reported, with Micromedex showing 464 DDI pairs and WebMD showing 600 pairs. Both databases classified 47 serious potential DDIs as contraindicated or major, with high concordance. The main predicted DDI mechanisms were immunosuppression (27%), methotrexate toxicity (18%), and nephrotoxicity (12%), with tacrolimus (12%), methotrexate (10%), and infliximab (6%) as major culprit drugs. In real-world co-prescriptions, 259 RA patients showed methotrexate/naproxen (46.4%) and methotrexate/sulfasalazine (29.5%) as the most common real-world co-prescribing patterns with potential DDIs. BrennanāPrediger kappa values indicated fair agreement (0.3161) in the electronic database predictions and conditional agreement (0.9807) among preselected serious DDIs. The LLM evaluation revealed that advanced models (e.g., Gemini 2.5 Pro) provided finesse recommendations highly concordant with expert opinion, whereas simpler models were more conservatively aligned with database alerts. Conclusion: In both real-world co-prescription and database evaluation, serious potential DDIs were associated mainly with methotrexate toxicity. Based on these exploratory findings, advanced LLMs show potential to assist with the contextualizing rigid database alerts and supporting pragmatic clinical decision-making. However, expert clinical judgment and direct patient consultation remain essential to improve RA patient safety and medication adherence.
- Open Access
Association of Obesity and Malnutrition with In-Hospital Mortality and Clinical Outcomes in Patients Receiving Maintenance Dialysis: A National Database Study
Background/Objectives: The study aimed to investigate whether malnutrition influences the obesity paradox and to explore the relationship between obesity with/without malnutrition and in-hospital outcomes among hospitalized ESKD patients. Methods: The study used the National Inpatient Sample database from 2016 to 2021. Hospitalized ESKD patients were included and categorized into three groups: non-obese, obese without malnutrition, and obese with malnutrition. The association between obesity with/without malnutrition and in-hospital outcomes, compared to non-obese patients, were analyzed. Results: Of 674,367 hospitalized ESKD patients included, 125,978 (18.7%) had obesity. Obese ESKD patients without malnutrition were associated with a decreased risk of mortality (odd ratio [OR] 0.87, 95% CI 0.84ā0.91), whereas obese patients with malnutrition were associated with an increased risk of mortality (OR 2.08, 95% CI 1.90ā2.27), compared to non-obese patients. Furthermore, obesity, with or without malnutrition, was linked to higher infection-related complications and resource utilization, especially when malnutrition was present. Conclusions: Our findings show that obesity is significantly associated with lower in-hospital mortality among ESKD patients without malnutrition. However, when malnutrition coexists, this survival advantage is reversed, underscoring the importance of detecting malnutrition in obese ESKD patients.
Open AccessAssociation of Obesity and Malnutrition with In-Hospital Mortality and Clinical Outcomes in Patients Receiving Maintenance Dialysis: A National Database Study
Background/Objectives: The study aimed to investigate whether malnutrition influences the obesity paradox and to explore the relationship between obesity with/without malnutrition and in-hospital outcomes among hospitalized ESKD patients. Methods: The study used the National Inpatient Sample database from 2016 to 2021. Hospitalized ESKD patients were included and categorized into three groups: non-obese, obese without malnutrition, and obese with malnutrition. The association between obesity with/without malnutrition and in-hospital outcomes, compared to non-obese patients, were analyzed. Results: Of 674,367 hospitalized ESKD patients included, 125,978 (18.7%) had obesity. Obese ESKD patients without malnutrition were associated with a decreased risk of mortality (odd ratio [OR] 0.87, 95% CI 0.84ā0.91), whereas obese patients with malnutrition were associated with an increased risk of mortality (OR 2.08, 95% CI 1.90ā2.27), compared to non-obese patients. Furthermore, obesity, with or without malnutrition, was linked to higher infection-related complications and resource utilization, especially when malnutrition was present. Conclusions: Our findings show that obesity is significantly associated with lower in-hospital mortality among ESKD patients without malnutrition. However, when malnutrition coexists, this survival advantage is reversed, underscoring the importance of detecting malnutrition in obese ESKD patients.
- Open Access
- 1 August 2025
- Published byĀ Taylor & FrancisĀ inĀ Drug Design, Development and Therapy
- Vol.Ā ume 19, 7427-7443
Discordance in DrugāDrug Interaction Alerts for Antidotes: Comparative Analysis of Electronic Databases and Interpretive Insights from AI Tools
Background: Drug-drug interactions (DDIs) are a critical clinical concern, especially when administering multiple medications, including antidotes. Despite their lifesaving potential, antidotes may interact harmfully with other drugs. However, few studies have specifically investigated DDIs involving antidotes. Purpose: This study evaluated potential DDIs between commonly prescribed medications and antidotes using two widely used electronic databases, along with artificial intelligence (AI) to assess the concordance between these platforms. Materials and Methods: A descriptive analysis was conducted using 50 frequently prescribed medications from the ClinCalc DrugStats Database (2022) and major antidotes as reported by California Poison Control Center. Potential interactions were assessed using Micromedex and WebMD as electronic databases, and ChatGPT and Google Gemini as representative AI. DDI severity levels and documentation quality were recorded, and database/AI agreement was analyzed using the kappa statistic. Results: Overall, 154 potential DDI pairs were identified by the databases (Micromedex: 100, WebMD: 118). Nineteen DDIs were classified as severe by both databases. The overall agreement between databases was poor (kappa = ā 0.126, p = 0.008), indicating significant discrepancies in DDI severity classification. The main mechanisms associated with severe DDIs included serotonin syndrome and QT prolongation, with methylene blue and psychiatric medications being major contributors to severe DDIs. When evaluating the 19 severe DDIs from both databases, the AI models generally aligned with the more severe rating in cases of database discordance. The AI modelsā consensus was often supported by severity-oriented justifications, highlighting this as a conservative approach to resolving discordant DDI information. Conclusion: Numerous potential DDIs between prescribed drugs and antidotes were identified, with notable inconsistencies between the two databases and AI. This underscores the need to harmonize DDI evaluation criteria across drug information systems and promote cliniciansā awareness of inter-database variability. Incorporating comprehensive DDI screening and shared decision-making is essential to ensure safe and effective patient care.
- 1 August 2025
- Published byĀ Taylor & FrancisĀ inĀ Drug Design, Development and Therapy
- Vol.Ā ume 19, 7427-7443
Open AccessDiscordance in DrugāDrug Interaction Alerts for Antidotes: Comparative Analysis of Electronic Databases and Interpretive Insights from AI Tools
Background: Drug-drug interactions (DDIs) are a critical clinical concern, especially when administering multiple medications, including antidotes. Despite their lifesaving potential, antidotes may interact harmfully with other drugs. However, few studies have specifically investigated DDIs involving antidotes. Purpose: This study evaluated potential DDIs between commonly prescribed medications and antidotes using two widely used electronic databases, along with artificial intelligence (AI) to assess the concordance between these platforms. Materials and Methods: A descriptive analysis was conducted using 50 frequently prescribed medications from the ClinCalc DrugStats Database (2022) and major antidotes as reported by California Poison Control Center. Potential interactions were assessed using Micromedex and WebMD as electronic databases, and ChatGPT and Google Gemini as representative AI. DDI severity levels and documentation quality were recorded, and database/AI agreement was analyzed using the kappa statistic. Results: Overall, 154 potential DDI pairs were identified by the databases (Micromedex: 100, WebMD: 118). Nineteen DDIs were classified as severe by both databases. The overall agreement between databases was poor (kappa = ā 0.126, p = 0.008), indicating significant discrepancies in DDI severity classification. The main mechanisms associated with severe DDIs included serotonin syndrome and QT prolongation, with methylene blue and psychiatric medications being major contributors to severe DDIs. When evaluating the 19 severe DDIs from both databases, the AI models generally aligned with the more severe rating in cases of database discordance. The AI modelsā consensus was often supported by severity-oriented justifications, highlighting this as a conservative approach to resolving discordant DDI information. Conclusion: Numerous potential DDIs between prescribed drugs and antidotes were identified, with notable inconsistencies between the two databases and AI. This underscores the need to harmonize DDI evaluation criteria across drug information systems and promote cliniciansā awareness of inter-database variability. Incorporating comprehensive DDI screening and shared decision-making is essential to ensure safe and effective patient care.
- Open Access
Temporal Trends and Clinical Impact of Malnutrition on In-Hospital Outcomes Among Patients with Advanced Chronic Kidney Disease: A Nationwide Inpatient Analysis
Background/Objectives: Malnutrition is a prevalent yet under-recognized condition in patients with advanced chronic kidney disease (CKD), contributing to increased morbidity, mortality, and healthcare burden. The aim of this study is to determine the prevalence and trends of malnutrition and investigate the impact of malnutrition on in-hospital outcomes, treatments, and resource utilization in hospitalized patients with advanced CKD. Methods: This study utilized the National Inpatient Sample (NIS) database to identify hospitalized patients with advanced CKD from 2016 to 2021. This study investigated temporal trends in the prevalence and in-hospital mortality across different degrees of malnutrition in advanced CKD patients. Multivariable regression models were used to assess the association between malnutrition and in-hospital outcomes. Results: Out of 1,244,415 advanced CKD patients, 67,587 (5.4%) had mild to moderate malnutrition, and 63,785 (5.1%) had severe malnutrition. Malnourished patients exhibited significantly higher in-hospital mortality, with adjusted odds ratios of 1.70 (95% confidence interval (CI), 1.64ā1.75) for mild to moderate cases and 2.67 (95% CI, 2.60ā2.75) for severe cases. Severely malnourished patients were associated with longer mean hospital stay by 7.0 days and higher hospitalization costs by $97,767 compared with non-malnourished patients. The prevalence of severe malnutrition showed a significant uptrend from 4.2% in 2016 to 5.5% in 2021 (p for trend < 0.001). Conclusions: Malnutrition in advanced CKD is an increasingly prevalent condition linked to worsened in-hospital outcomes and heightened healthcare resource utilization. The rising trend of severe malnutrition underscores the need for early nutritional screening and the need for future interventional studies to mitigate adverse clinical outcomes in this high-risk population.
Open AccessTemporal Trends and Clinical Impact of Malnutrition on In-Hospital Outcomes Among Patients with Advanced Chronic Kidney Disease: A Nationwide Inpatient Analysis
Background/Objectives: Malnutrition is a prevalent yet under-recognized condition in patients with advanced chronic kidney disease (CKD), contributing to increased morbidity, mortality, and healthcare burden. The aim of this study is to determine the prevalence and trends of malnutrition and investigate the impact of malnutrition on in-hospital outcomes, treatments, and resource utilization in hospitalized patients with advanced CKD. Methods: This study utilized the National Inpatient Sample (NIS) database to identify hospitalized patients with advanced CKD from 2016 to 2021. This study investigated temporal trends in the prevalence and in-hospital mortality across different degrees of malnutrition in advanced CKD patients. Multivariable regression models were used to assess the association between malnutrition and in-hospital outcomes. Results: Out of 1,244,415 advanced CKD patients, 67,587 (5.4%) had mild to moderate malnutrition, and 63,785 (5.1%) had severe malnutrition. Malnourished patients exhibited significantly higher in-hospital mortality, with adjusted odds ratios of 1.70 (95% confidence interval (CI), 1.64ā1.75) for mild to moderate cases and 2.67 (95% CI, 2.60ā2.75) for severe cases. Severely malnourished patients were associated with longer mean hospital stay by 7.0 days and higher hospitalization costs by $97,767 compared with non-malnourished patients. The prevalence of severe malnutrition showed a significant uptrend from 4.2% in 2016 to 5.5% in 2021 (p for trend < 0.001). Conclusions: Malnutrition in advanced CKD is an increasingly prevalent condition linked to worsened in-hospital outcomes and heightened healthcare resource utilization. The rising trend of severe malnutrition underscores the need for early nutritional screening and the need for future interventional studies to mitigate adverse clinical outcomes in this high-risk population.
- Open Access
- 27 March 2025
- Published byĀ MDPI AGĀ inĀ Journal of Clinical Medicine
- Vol.Ā 14 Ā (7) , 2284
Outcomes of Kidney Transplant Recipients Versus Non-Recipients in the Intensive Care Unit: A Systematic Review and Meta-Analysis
Background/Objectives: With the growing population of kidney transplant recipients (KTRs) in intensive care units (ICUs), understanding their prognostic outcomes is critical. As conflicting findings exist, we aim to systematically evaluate and meta-analyze ICU outcomes in kidney transplant recipients compared to non-recipients. Methods: We conducted a comprehensive search of the PubMed, Embase, and Cochrane databases, from inception through 23 December 2024, to identify relevant studies comparing the outcomes of KTRs and non-transplant ICU patients. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes, and weighted mean differences (WMDs) were calculated for continuous outcomes. The risk of bias was assessed using the ROBINS-I V2 tool. The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD42024595104). Results: Seven studies, including 12,062 patients, were analyzed. Demographics, including age and sex, were comparable across groups. No statistically significant associations were found for overall mortality (OR: 1.82, 95% CI: 0.79 to 4.16), ICU mortality (OR: 1.06, 95% CI: 0.45 to 2.48), or 28/30-day mortality (OR: 2.06, 95% CI: 0.30 to 14.10) in KTRs, though there was a trend suggesting a potential increase in the odds of overall mortality. KTRs tended to have longer ICU stays (WMD: +1.96 days, 95% CI: 0.81ā3.11) and higher Sequential Organ Failure Assessment (SOFA) scores (WMD: +0.79, 95% CI: ā0.78ā2.36), but these findings did not reach statistical significance. One study reported higher 1-year and 5-year mortality for KTRs. Sensitivity analyses revealed one influential study. Beggās test for overall mortality suggested non-significant publication bias (p = 1.0). Conclusions: KTRs in ICUs are at significantly higher risk for long-term mortality, emphasizing the need for tailored critical care strategies and long-term management. Future research should focus on standardizing methodologies, reducing heterogeneity, and addressing gaps in data to improve evidence-based care for this vulnerable population.
- 27 March 2025
- Published byĀ MDPI AGĀ inĀ Journal of Clinical Medicine
- Vol.Ā 14 Ā (7) , 2284
Open AccessOutcomes of Kidney Transplant Recipients Versus Non-Recipients in the Intensive Care Unit: A Systematic Review and Meta-Analysis
Background/Objectives: With the growing population of kidney transplant recipients (KTRs) in intensive care units (ICUs), understanding their prognostic outcomes is critical. As conflicting findings exist, we aim to systematically evaluate and meta-analyze ICU outcomes in kidney transplant recipients compared to non-recipients. Methods: We conducted a comprehensive search of the PubMed, Embase, and Cochrane databases, from inception through 23 December 2024, to identify relevant studies comparing the outcomes of KTRs and non-transplant ICU patients. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes, and weighted mean differences (WMDs) were calculated for continuous outcomes. The risk of bias was assessed using the ROBINS-I V2 tool. The study protocol was registered in the International Prospective Register of Systematic Reviews (CRD42024595104). Results: Seven studies, including 12,062 patients, were analyzed. Demographics, including age and sex, were comparable across groups. No statistically significant associations were found for overall mortality (OR: 1.82, 95% CI: 0.79 to 4.16), ICU mortality (OR: 1.06, 95% CI: 0.45 to 2.48), or 28/30-day mortality (OR: 2.06, 95% CI: 0.30 to 14.10) in KTRs, though there was a trend suggesting a potential increase in the odds of overall mortality. KTRs tended to have longer ICU stays (WMD: +1.96 days, 95% CI: 0.81ā3.11) and higher Sequential Organ Failure Assessment (SOFA) scores (WMD: +0.79, 95% CI: ā0.78ā2.36), but these findings did not reach statistical significance. One study reported higher 1-year and 5-year mortality for KTRs. Sensitivity analyses revealed one influential study. Beggās test for overall mortality suggested non-significant publication bias (p = 1.0). Conclusions: KTRs in ICUs are at significantly higher risk for long-term mortality, emphasizing the need for tailored critical care strategies and long-term management. Future research should focus on standardizing methodologies, reducing heterogeneity, and addressing gaps in data to improve evidence-based care for this vulnerable population.
- 5 October 2024
- Published byĀ WileyĀ inĀ Clinical Transplantation
- Vol.Ā 38 Ā (10) , e15470
Reexamining Transplant Outcomes in Acute Kidney Injury Kidneys Through Machine Learning
Background: Despite many people awaiting kidney transplant, kidney allografts from acute kidney injury (AKI) donors continue to be underutilized. We aimed to cluster kidney transplant recipients of AKI kidney allografts using an unsupervised machine learning (ML) approach.Methods: Using Organ Procurement and Transplantation NetworkāUnited Network for Organ Sharing (OPTN/UNOS) data, a consensus clustering cohort analysis was performed in 12 356 deceased donor kidney transplant recipients between 2015 and 2019 in whom donors had a terminal serum creatinine ā„1.5 mg/dL. Significant cluster characteristics were determined, and outcomes were compared.Results: The median donor terminal creatinine was 2.2 (interquartile range [IQR] 1.7ā3.3) mg/dL. Cluster analysis was performed on 12 356 AKI kidney recipients, and three clinically distinct clusters were identified. Young, sensitized kidney reātransplant patients characterized Cluster 1. Cluster 2 was characterized by firstātime kidney transplant patients with hypertensive and diabetic kidney diseases. Older diabetic recipients characterized Cluster 3. Clusters 1 and 2 donors were young and met standard kidney donor profile index (KDPI) criteria; Cluster 3 donors were older, more likely to have hypertension or diabetes, and meet high KDPI criteria. Cluster 1 had a higher risk of acute rejection, 3āyear patient death, and graft failure. Cluster 3 had a higher risk of deathācensored graft failure, patient death, and graft failure at 1 and 3 years. Cluster 2 had the best patientā, graftā, and deathācensored graft survival at 1 and 3 years. Compared to nonāAKI kidney recipients, the AKI clusters showed a higher incidence of delayed graft function (DGF, AKI: 43.2%, 41.7%, 45.3% vs. nonāAKI: 25.5%); however, there were comparable longāterm outcomes specific to deathācensored graft survival (AKI: 93.6%, 93.4%, 90.4% vs. nonāAKI: 92.3%), patient survival (AKI: 89.1%, 93.2%, 84.2% vs. nonāAKI: 91.2%), and overall graft survival (AKI: 84.7%, 88.2%, 79.0% vs. nonāAKI: 86.0%).Conclusions: In this unsupervised ML approach study, AKI recipient clusters demonstrated differing, but good clinical outcomes, suggesting opportunities for transplant centers to incrementally increase kidney utilization from AKI donors.
- 5 October 2024
- Published byĀ WileyĀ inĀ Clinical Transplantation
- Vol.Ā 38 Ā (10) , e15470
Reexamining Transplant Outcomes in Acute Kidney Injury Kidneys Through Machine Learning
Background: Despite many people awaiting kidney transplant, kidney allografts from acute kidney injury (AKI) donors continue to be underutilized. We aimed to cluster kidney transplant recipients of AKI kidney allografts using an unsupervised machine learning (ML) approach.Methods: Using Organ Procurement and Transplantation NetworkāUnited Network for Organ Sharing (OPTN/UNOS) data, a consensus clustering cohort analysis was performed in 12 356 deceased donor kidney transplant recipients between 2015 and 2019 in whom donors had a terminal serum creatinine ā„1.5 mg/dL. Significant cluster characteristics were determined, and outcomes were compared.Results: The median donor terminal creatinine was 2.2 (interquartile range [IQR] 1.7ā3.3) mg/dL. Cluster analysis was performed on 12 356 AKI kidney recipients, and three clinically distinct clusters were identified. Young, sensitized kidney reātransplant patients characterized Cluster 1. Cluster 2 was characterized by firstātime kidney transplant patients with hypertensive and diabetic kidney diseases. Older diabetic recipients characterized Cluster 3. Clusters 1 and 2 donors were young and met standard kidney donor profile index (KDPI) criteria; Cluster 3 donors were older, more likely to have hypertension or diabetes, and meet high KDPI criteria. Cluster 1 had a higher risk of acute rejection, 3āyear patient death, and graft failure. Cluster 3 had a higher risk of deathācensored graft failure, patient death, and graft failure at 1 and 3 years. Cluster 2 had the best patientā, graftā, and deathācensored graft survival at 1 and 3 years. Compared to nonāAKI kidney recipients, the AKI clusters showed a higher incidence of delayed graft function (DGF, AKI: 43.2%, 41.7%, 45.3% vs. nonāAKI: 25.5%); however, there were comparable longāterm outcomes specific to deathācensored graft survival (AKI: 93.6%, 93.4%, 90.4% vs. nonāAKI: 92.3%), patient survival (AKI: 89.1%, 93.2%, 84.2% vs. nonāAKI: 91.2%), and overall graft survival (AKI: 84.7%, 88.2%, 79.0% vs. nonāAKI: 86.0%).Conclusions: In this unsupervised ML approach study, AKI recipient clusters demonstrated differing, but good clinical outcomes, suggesting opportunities for transplant centers to incrementally increase kidney utilization from AKI donors.
- Open Access
- 7 February 2024
- Published byĀ ElsevierĀ inĀ Food and Chemical Toxicology
- Vol.Ā 185, 114509
Sub-chronic oral toxicity of a water-soluble extract of Centella asiatica (Centell-S) in Wistar rats
- 7 February 2024
- Published byĀ ElsevierĀ inĀ Food and Chemical Toxicology
- Vol.Ā 185, 114509
Open AccessSub-chronic oral toxicity of a water-soluble extract of Centella asiatica (Centell-S) in Wistar rats
- 1 December 2023
- Published byĀ WileyĀ inĀ Clinical Transplantation
- Vol.Ā 38 Ā (1) , e15201
Reāassessing prolonged cold ischemia time in kidney transplantation through machine learning consensus clustering
Background: We aimed to cluster deceased donor kidney transplant recipients with prolonged cold ischemia time (CIT) using an unsupervised machine learning approach.Methods: We performed consensus cluster analysis on 11 615 deceased donor kidney transplant patients with CIT exceeding 24 h using OPTN/UNOS data from 2015 to 2019. Cluster characteristics of clinical significance were identified, and postātransplant outcomes were compared.Results: Consensus cluster analysis identified two clinically distinct clusters. Cluster 1 was characterized by young, nonādiabetic patients who received kidney transplants from young, nonāhypertensive, nonāECD deceased donors with lower KDPI scores. In contrast, the patients in cluster 2 were older and more likely to have diabetes. Cluster 2 recipients were more likely to receive transplants from older donors with a higher KDPI. There was lower use of machine perfusion in Cluster 1 and incrementally longer CIT in Cluster 2. Cluster 2 had a higher incidence of delayed graft function (42% vs. 29%), and lower 1āyear patient (95% vs. 98%) and deathācensored (95% vs. 97%) graft survival compared to Cluster 1.Conclusions: Unsupervised machine learning characterized deceased donor kidney transplant recipients with prolonged CIT into two clusters with differing outcomes. Although Cluster 1 had more favorable recipient and donor characteristics and better survival, the outcomes observed in Cluster 2 were also satisfactory. Overall, both clusters demonstrated good survival suggesting opportunities for transplant centers to incrementally increase CIT.
- 1 December 2023
- Published byĀ WileyĀ inĀ Clinical Transplantation
- Vol.Ā 38 Ā (1) , e15201
Reāassessing prolonged cold ischemia time in kidney transplantation through machine learning consensus clustering
Background: We aimed to cluster deceased donor kidney transplant recipients with prolonged cold ischemia time (CIT) using an unsupervised machine learning approach.Methods: We performed consensus cluster analysis on 11 615 deceased donor kidney transplant patients with CIT exceeding 24 h using OPTN/UNOS data from 2015 to 2019. Cluster characteristics of clinical significance were identified, and postātransplant outcomes were compared.Results: Consensus cluster analysis identified two clinically distinct clusters. Cluster 1 was characterized by young, nonādiabetic patients who received kidney transplants from young, nonāhypertensive, nonāECD deceased donors with lower KDPI scores. In contrast, the patients in cluster 2 were older and more likely to have diabetes. Cluster 2 recipients were more likely to receive transplants from older donors with a higher KDPI. There was lower use of machine perfusion in Cluster 1 and incrementally longer CIT in Cluster 2. Cluster 2 had a higher incidence of delayed graft function (42% vs. 29%), and lower 1āyear patient (95% vs. 98%) and deathācensored (95% vs. 97%) graft survival compared to Cluster 1.Conclusions: Unsupervised machine learning characterized deceased donor kidney transplant recipients with prolonged CIT into two clusters with differing outcomes. Although Cluster 1 had more favorable recipient and donor characteristics and better survival, the outcomes observed in Cluster 2 were also satisfactory. Overall, both clusters demonstrated good survival suggesting opportunities for transplant centers to incrementally increase CIT.
- Open Access
- 16 November 2023
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 18 Ā (11) , e0293866
Potential drugādrug interactions of frequently prescribed medications in long COVID detected by two electronic databases
Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a wide range of acute and chronic complications including long COVID, a well-known chronic sequela. Long COVID often necessitates long-term treatment, which may lead to an increased potential for drugādrug interactions (DDIs). The objective of this study was to assess potential DDIs among frequently prescribed medications in long COVID by using two electronic databases. Sixty frequently prescribed agents were selected from Thailandās National List of Essential Medicine 2022 for potential DDI analysis by Micromedex and Drugs.com. From these databases, 488 potential DDIs were identified. There were 271 and 434 DDI pairs based on Micromedex and Drugs.com, respectively. Among these DDIs, 77 pairs were labeled as contraindicated or major by both databases. The most common mechanisms for these serious interactions are cytochrome P450 (CYP) inhibition (45%), CYP induction (19%), and QT interval prolongation (7.8%). Based on Fleissā kappa (0.073), there was only slight agreement of the DDI severity classifications between these two databases. In conclusion, a large number of potential DDIs were detected among frequently prescribed medications for long COVID. Health care providers should be aware of these DDIs, particularly those that are deemed as contraindicated or major. These DDIs are most likely to cause significant adverse events in patients with long COVID because polypharmacy is common.
- 16 November 2023
- Published byĀ Public Library of Science (PLoS)Ā inĀ PLOS ONE
- Vol.Ā 18 Ā (11) , e0293866
Open AccessPotential drugādrug interactions of frequently prescribed medications in long COVID detected by two electronic databases
Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a wide range of acute and chronic complications including long COVID, a well-known chronic sequela. Long COVID often necessitates long-term treatment, which may lead to an increased potential for drugādrug interactions (DDIs). The objective of this study was to assess potential DDIs among frequently prescribed medications in long COVID by using two electronic databases. Sixty frequently prescribed agents were selected from Thailandās National List of Essential Medicine 2022 for potential DDI analysis by Micromedex and Drugs.com. From these databases, 488 potential DDIs were identified. There were 271 and 434 DDI pairs based on Micromedex and Drugs.com, respectively. Among these DDIs, 77 pairs were labeled as contraindicated or major by both databases. The most common mechanisms for these serious interactions are cytochrome P450 (CYP) inhibition (45%), CYP induction (19%), and QT interval prolongation (7.8%). Based on Fleissā kappa (0.073), there was only slight agreement of the DDI severity classifications between these two databases. In conclusion, a large number of potential DDIs were detected among frequently prescribed medications for long COVID. Health care providers should be aware of these DDIs, particularly those that are deemed as contraindicated or major. These DDIs are most likely to cause significant adverse events in patients with long COVID because polypharmacy is common.
- Top Cited PapersOpen Access
- 26 September 2023
- Published byĀ MDPI AGĀ inĀ Clinics and Practice
- Vol.Ā 13 Ā (5) , 1160-1172
AI-Powered Renal Diet Support: Performance of ChatGPT, Bard AI, and Bing Chat
Patients with chronic kidney disease (CKD) necessitate specialized renal diets to prevent complications such as hyperkalemia and hyperphosphatemia. A comprehensive assessment of food components is pivotal, yet burdensome for healthcare providers. With evolving artificial intelligence (AI) technology, models such as ChatGPT, Bard AI, and Bing Chat can be instrumental in educating patients and assisting professionals. To gauge the efficacy of different AI models in discerning potassium and phosphorus content in foods, four AI modelsāChatGPT 3.5, ChatGPT 4, Bard AI, and Bing Chatāwere evaluated. A total of 240 food items, curated from the Mayo Clinic Renal Diet Handbook for CKD patients, were input into each model. These items were characterized by their potassium (149 items) and phosphorus (91 items) content. Each model was tasked to categorize the items into high or low potassium and high phosphorus content. The results were juxtaposed with the Mayo Clinic Renal Diet Handbookās recommendations. The concordance between repeated sessions was also evaluated to assess model consistency. Among the models tested, ChatGPT 4 displayed superior performance in identifying potassium content, correctly classifying 81% of the foods. It accurately discerned 60% of low potassium and 99% of high potassium foods. In comparison, ChatGPT 3.5 exhibited a 66% accuracy rate. Bard AI and Bing Chat models had an accuracy rate of 79% and 81%, respectively. Regarding phosphorus content, Bard AI stood out with a flawless 100% accuracy rate. ChatGPT 3.5 and Bing Chat recognized 85% and 89% of the high phosphorus foods correctly, while ChatGPT 4 registered a 77% accuracy rate. Emerging AI models manifest a diverse range of accuracy in discerning potassium and phosphorus content in foods suitable for CKD patients. ChatGPT 4, in particular, showed a marked improvement over its predecessor, especially in detecting potassium content. The Bard AI model exhibited exceptional precision for phosphorus identification. This study underscores the potential of AI models as efficient tools in renal dietary planning, though refinements are warranted for optimal utility.
- 26 September 2023
- Published byĀ MDPI AGĀ inĀ Clinics and Practice
- Vol.Ā 13 Ā (5) , 1160-1172
Top Cited PapersOpen AccessAI-Powered Renal Diet Support: Performance of ChatGPT, Bard AI, and Bing Chat
Patients with chronic kidney disease (CKD) necessitate specialized renal diets to prevent complications such as hyperkalemia and hyperphosphatemia. A comprehensive assessment of food components is pivotal, yet burdensome for healthcare providers. With evolving artificial intelligence (AI) technology, models such as ChatGPT, Bard AI, and Bing Chat can be instrumental in educating patients and assisting professionals. To gauge the efficacy of different AI models in discerning potassium and phosphorus content in foods, four AI modelsāChatGPT 3.5, ChatGPT 4, Bard AI, and Bing Chatāwere evaluated. A total of 240 food items, curated from the Mayo Clinic Renal Diet Handbook for CKD patients, were input into each model. These items were characterized by their potassium (149 items) and phosphorus (91 items) content. Each model was tasked to categorize the items into high or low potassium and high phosphorus content. The results were juxtaposed with the Mayo Clinic Renal Diet Handbookās recommendations. The concordance between repeated sessions was also evaluated to assess model consistency. Among the models tested, ChatGPT 4 displayed superior performance in identifying potassium content, correctly classifying 81% of the foods. It accurately discerned 60% of low potassium and 99% of high potassium foods. In comparison, ChatGPT 3.5 exhibited a 66% accuracy rate. Bard AI and Bing Chat models had an accuracy rate of 79% and 81%, respectively. Regarding phosphorus content, Bard AI stood out with a flawless 100% accuracy rate. ChatGPT 3.5 and Bing Chat recognized 85% and 89% of the high phosphorus foods correctly, while ChatGPT 4 registered a 77% accuracy rate. Emerging AI models manifest a diverse range of accuracy in discerning potassium and phosphorus content in foods suitable for CKD patients. ChatGPT 4, in particular, showed a marked improvement over its predecessor, especially in detecting potassium content. The Bard AI model exhibited exceptional precision for phosphorus identification. This study underscores the potential of AI models as efficient tools in renal dietary planning, though refinements are warranted for optimal utility.